U.S. Markets closed

The Market In 5 Minutes: Italy, ASCO, Roku And More

Benzinga Newsdesk

IN THE NEWS

Political worries about Italy and Spain gripped markets Tuesday, triggering sharp falls in stocks, a drop in the euro and big moves in bond markets: Link $

Apple Inc. (NASDAQ: AAPL) analysts are moving toward a sure consensus: growth is in the Services. The lessened emphasis on hardware has yielded new investment approaches: Link

A consolidation wave is sweeping across the marijuana industry, as companies aim to improve their competitive positioning and market share in an industry which offers a lot of promise: Link

With earnings season winding down, FDA decisions and ASCO data presentations will be some of the notable catalysts in the biotech sector this week: Link

Founders of highflying startups are increasingly wresting control of their companies from venture-capital backers and extracting huge pay packages tied to going public: Link $

Fed's Bullard warns against rate hikes: Link $

Maybe AT&T’s (NYSE: T) $85 billion merger with Time Warner (NYSE: TWX) is in trouble, after all: Link

ECONOMIC DATA

  • USA S&P/CS HPI Composite - 20 n.s.a. (YoY) for Mar 6.80% vs 6.40% Est; Prior 6.80%
  • The Conference Board’s consumer confidence index for May will be released at 10:00 a.m. ET.
  • The Dallas Fed manufacturing index for May is schedule for release at 10:30 a.m. ET.
  • The Treasury is set to auction 3-and 6-month bills at 11:30 a.m. ET.
  • The Treasury will auction 4-week bills at 1:00 p.m. ET.

ANALYST RATINGS

  • Morgan Stanley upgrades Roku (NASDAQ: ROKU) from Underweight to Equal-Weight
  • KBW upgrades Federated Investors (NYSE: FII) from Underperform to Market Perform
  • HSBC downgrades Novartis (NYSE: NVS) from Buy to Hold
  • Jefferies downgrades Infinera (NASDAQ: INFN) from Hold to Underperform

This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

See more from Benzinga

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.